Ariana Pelosci

T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.

Results from the Beamion LUNG-1 study showed that first-line zongertinib yielded continued benefit for patients with HER2-mutated NSCLC.

Experts discuss various treatment options for patients with HER2-positive breast cancer, and which would benefit the most based on their characteristics.

The RadComp Consortium trial showed comparable HRQOL between proton and photon therapy for patients with non-metastatic breast cancer.

Regarding feeding tube use and weight loss, patients with oropharyngeal cancer treated with proton beam therapy or IMRT saw similar results.

In the oncology setting, having discussions about mortality and death may be daunting for patients, but is vital and inevitable.

An 80% disease metastasis–free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.

In an interim safety analysis, no dose-limiting toxicities, unexpected AEs, or grade 3/4 AEs were reported in 10 patients treated for metastatic CRPC.

The VGPR or better rate was 87.8% in patients treated with Isa-VRd who had transplant-ineligible newly diagnosed multiple myeloma.

As a 1-time dose, arlo-cel yielded promising efficacy and safety for patients with previously treated relapsed/refractory multiple myeloma.

Adverse effects were manageable when patients with heavily pretreated multiple myeloma were given cevostamab consolidation after receiving CAR T-cell therapy.

Clinicians discuss the best treatment options for a 46-year-old woman diagnosed with BRAF+ melanoma.

Gary Steinberg, MD, highlights the FDA approval of the gemcitabine intravesical system and what this means for patients with BCG-unresponsive NMIBC.

Results from the DeLLphi-303 trial showed sustained efficacy and safety with tarlatamab plus anti–PD-1 treatment for patients with extensive-stage SCLC.

In patients who refuse or are ineligible for radical cystectomy, the gemcitabine intravesical system may be given after unsuccessful BCG treatment.

For patients with unresectable stage III NSCLC, concurrent durvalumab with chemotherapy/radiation did not show an efficacy improvement.

The modified overall response rate was higher with venetoclax/azacitidine vs placebo/azacitidine in patients with intermediate/high risk MDS.

Results from the phase 3 MIRASOL trial led to the approval of mirvetuximab soravtansine for patients with FRα+ ovarian cancer.

Results from the Beamion-LUNG 1 trial showed an ORR of 75% for patients with HER2+ NSCLC treated with zongertinib.

Leveraging #WCLC25, lung oncologists spoke about the presentations they’re most looking forward to at the upcoming conference.

Updates on treatments like vusolimogene oderparepvec for advanced melanoma, and novel therapies have been provided by the FDA.

Only 2 patients died in the phase 3 trial evaluating interferon-alpha in adult patients with cancer, but were deemed unrelated to study treatment.

Pediatric patients self-reported symptom burden using the SSPedi tool, which observed symptom burden from baseline, 4 weeks, and 8 weeks.

Boris M. Kiselev, MD, discusses the role of psycho-oncology in comprehensive cancer care, addressing barriers and offering a vision for the field’s future.

Results from a phase 3 trial led to the approval of leuprolide mesylate as a 3-month formulation for patients with advanced prostate cancer.

Results from the monarchE study showed a statistically significant OS improvement with abemaciclib plus ET for patients with HR+/HER2– early breast cancer.

The novel treatment was evaluated in a phase 2 trial and saw a clinical benefit in patients with advanced ovarian cancer.

Declan Walsh, MD, highlighted how the supportive and palliative care space has evolved since he first began working in the field.

Results from the phase 3 VERIFY trial of rusfertide for erythrocytosis in patients with polycythemia vera led to the FDA decision.

The Chemo Mouthpiece had favorable outcomes when used during and after treatment with chemotherapy among a range of patients with various types of cancer.